

Special Issue

Protein Therapy for Cardiovascular Disease Treatment

Message from the Guest Editors

Myocardial infarction (MI) occurs due to the blockage of coronary arteries, leading to ischemia of the myocardium and inflammatory cell death. The dead cardiac tissue is replaced by fibrous scar tissue, causing a decline in myocardial contractile strength and impacting the functional capacity of the heart. While treatments such as stent placement, vascular bypass, and transplantation are beneficial, they have limitations. There is an urgent need to develop novel protein therapeutics to control inflammation and to improve the regenerative capacity of the heart in the setting of acute MI and chronic heart failure. New approaches involving biologics, cell-based, or a combination of biologics and cell therapies are emerging as potential means for cardiovascular diseases. The development of an effective delivery system is crucial to ensure that therapeutic proteins reach the target tissues in the body. The exploration of various methods, including injections, implants, and other advanced drug and cell delivery technologies, is essential for this purpose.

Guest Editors

Prof. Dr. Jianjie Ma

Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA

Dr. Ki Ho Park

Department of Surgery, Division of Surgical Sciences, University of Virginia, Charlottesville, VA, USA

Deadline for manuscript submissions

closed (31 January 2025)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/196911

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.